Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

A. Socinski, Mark; M. Jotte, Robert; Cappuzzo, Federico; Orlandi, Francesco; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodríguez‐Abreu, Delvys; Moro‐Sibilot, Denis; A. Thomas, Christian; Barlési, Fabrice; Grant Finley, Gene; Kelsch, Claudia; Lee, Anthony; Coleman, Shelley; Deng, Yu; Shen, Yijing; Kowanetz, Marcin; López-Chávez, Ariel; Sandler, Alan; Reck, Martin

doi:10.1056/nejmoa1716948

Public

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Published in New England Journal of Medicine • Jun 4, 2018

Authors:

Mark A. Socinski

Robert M. Jotte

Federico Cappuzzo

Abstract

BACKGROUND: The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsqua...

Subject

Atezolizumab

Oncology

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!